After Trump Rescinds Executive Order, Future of Drug Pricing Models Remains Unclear
-
Jan 23, 2025
Shortly after taking office, President Donald Trump on Jan. 20 rescinded numerous executive orders that were put in place under his predecessor, Joe Biden — including one that led to the introduction of three CMS drug pricing pilot programs. However, experts say it's still unclear what Trump’s move indicates for the future of the models.
Biden issued his order in October 2022 to address lowering prescription drug costs through the CMS Center for Medicare and Medicaid Innovation (CMMI). In February 2023, CMMI announced three models under consideration, including the Cell and Gene Therapy (CGT) Access Model, the Accelerating Clinical Evidence Model and the Medicare $2 Drug List Model. The CGT model is the furthest along and is set to launch this year, while the other two models are still in the planning stages.
Read more
© 2024 MMIT
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.